July 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of ...
Cellular proteins are subject to numerous post-translational modifications (PTMs), which control many aspects of cellular function. Such modifications can regulate protein activity through allosteric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results